抗肿瘤新药:首个VEGF抑制剂Bevacizumab上市

摘要：

@@ In February 2004, bevacizumab (Avastin; Genentech), an antibody against vascularendothelial growth factor, was approved by the US FDA for the first-line treatment of metastatic colorectal cancer, a leading cause of cancer deaths worldwide.

机标关键词：抗肿瘤新药、抑制剂、metastatic colorectal cancer、growth factor

所属期刊栏目：27

分类号：R97;R73

在线出版日期：2005-06-16（万方平台首次上网日期，不代表论文的发表时间）

页数：共4页

页码：608-611